IPPRA / Grant Monitor

2026-07-07
← Board

DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award

HT942526ALSRPCOBA · Defense Health Agency Contracting Activity - DHACA

biomedical clinical ai data science public health Science & Technology R&D

Closes
2026-09-30 · 85 d
Award ceiling
Award floor
Program funding
$7,000,000
Expected awards
7
Cost sharing
No
Posted
2026-05-04
Instrument
Grant
Characterization · gpt-5.4-mini · 2026-07-07

This award funds development and/or validation of ALS clinical outcomes and biomarkers, including digital health measures, to improve or enrich clinical trials for ALS.

Funds
applied research
University
direct
social behavioral
minor
physical sciences
minor
engineering
minor
life biomedical
central
computational data
substantial

⚑ Community collaboration with the ALS lived experience community is expected. · Projects may target a specific therapy, therapeutic class, or ALS subtype; broad applicability to all ALS patients is not required.

Unit fits — one characterization, each unit's own rules

Physical Sciences & Engineering (demo) 80 strong technical depth: substantial; funds applied research
IPPRA 58 good peripheral portfolio topic: public_health; signature methods: community engaged; social/behavioral work is minor; funds applied research; biomedical core — IPPRA health lane is communication/crisis/policy (capped); clinical-trial/biomedical core — IPPRA angle is policy/community (capped)
Tom Love Innovation Hub 30 weak funds applied research; deep-tech content

Description

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients.

Distinctive Features: To meet the intent of the funding opportunity, applications may address clinical biomarkers and/or clinical outcomes . This may include the identification, development, and/or validation of promising biomarkers for ALS, which may include, but are not limited to susceptibility/risk, diagnostic, monitoring/disease progression, prognostic, predictive, response, or safety biomarkers. Clinical Outcomes projects may focus on the identification, development, and/or validation of clinician-, observer-, or patient-reported, and/or performance outcome measures for ALS. Projects may include the optimization of current outcome measures already in use.

Applications may utilize digital health measures, including wearable devices, smart-phone sensors, video or voice recordings, imaging studies, or other devices which record disease-relevant physiological data and/or outcomes.

Community Collaboration is an important element of the FY26 ALSRP COBA. Applicants will be expected to articulate how the proposed research question or study design was informed by the

ALS lived experience community.

Apply

View on Grants.gov → CONTACT: Jamie Shortall Grant Officer <help@eBRAP.org>

Proposal brief SEE AN EXAMPLE →

A one-page internal memo: fit assessment, submission requirements, document scaffold, and next steps dated back from the deadline — tailored to your project idea if you add one.

ONE LLM CALL (~1¢) · CACHED · REQUIRES STAFF KEY

Proposal shell · Department of Defense (BAA-style) conventions SEE A DOD EXAMPLE →

Funder-faithful document skeletons — Department of Defense (BAA-style)'s document set with section headings, page limits, reviewer guidance, and writing prompts; add a project idea to get [DRAFT] starter bullets. Download as .md for Word or Overleaf.

ONE LLM CALL (~2-3¢) · CACHED · SCAFFOLDING, NOT GHOSTWRITING